Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 20
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of Epicardial Adipose Tissue on Infarct Size and Left Ventricular Systolic Function in Patients with Anterior ST-Segment Elevation Myocardial Infarction

  • Gavara Doñate, Jose|||0000-0002-3483-7066
  • Merenciano, Héctor|||0000-0002-1734-0381
  • Llopis-Lorente, Jordi|||0000-0002-3958-8062
  • Molina-Garcia, Tamara
  • Perez-Solé, Nerea|||0000-0003-3527-0337
  • de Dios, Elena
  • Marcos-Garces, Víctor
  • Monmeneu, José V.
  • Lopez-Lereu, María P.
  • Canoves, Joaquim
  • Bonanad, Clara
  • Moratal, David|||0000-0002-2825-3646
  • Núñez, Julio|||0000-0003-1672-7119
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Sanchis, Juan|||0000-0003-0797-8709
  • Chorro, Francisco J.
  • Rios-Navarro, Cesar|||0000-0002-6405-6279
  • Bodi, Vicente|||0000-0001-6425-5828
We aimed to assess the correlation of cardiovascular magnetic resonance (CMR)-derived epicardial adipose tissue (EAT) with infarct size (IS) and residual systolic function in ST-segment elevation myocardial infarction (STEMI). We enrolled patients discharged for a first anterior reperfused STEMI submitted to undergo CMR. EAT, left ventricular (LV) ejection fraction (LVEF), and IS were quantified at the 1-week (n = 221) and at 6-month CMR (n = 167). At 1-week CMR, mean EAT was 31 ± 13 mL/m. Patients with high EAT volume (n = 72) showed larger 1-week IS. After adjustment, EAT extent was independently related to 1-week IS. In patients with large IS at 1 week (>30% of LV mass, n = 88), those with high EAT showed more preserved 6-month LVEF. This association persisted after adjustment and in a 1:1 propensity score-matched patient subset. Overall, EAT decreased at 6 months. In patients with large IS, a greater reduction of EAT was associated with more preserved 6-month LVEF. In STEMI, a higher presence of EAT was associated with a larger IS. Nevertheless, in patients with large infarctions, high EAT and greater subsequent EAT reduction were linked to more preserved LVEF in the chronic phase. This dual and paradoxical effect of EAT fuels the need for further research in this field.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Biomarkers to Improve Decision-making in Acute Heart Failure

  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Núñez-Marín, Gonzalo|||0000-0003-2867-5344
  • Codina, Pau|||0000-0002-2469-5711
  • Núñez, Julio|||0000-0003-1672-7119
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Acute heart failure (AHF) is a complex clinical syndrome that requires prompt diagnosis, risk stratification and effective treatment strategies to reduce morbidity and mortality. Biomarkers are playing an increasingly important role in this process, offering valuable insights into the underlying pathophysiology and facilitating personalised patient management. This review summarises the significance of various biomarkers in the context of AHF, with a focus on their clinical applications to stratify risk and potential for guiding therapy choices.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cytokine Networks and Heart Failure Outcomes, CA125 as a Bridge Between Congestion and Inflammation

  • Santas, Enrique
  • Martí-Martínez, Arancha
  • Villar, Sandra|||0000-0001-8229-6279
  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Rodriguez-Borja, Enrique|||0000-0002-0339-6704
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • González, Arantxa|||0000-0001-5986-6528
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Sanchis, Juan|||0000-0003-0797-8709
  • Núñez, Julio|||0000-0003-1672-7119
Inflammation and congestion constitute fundamental mechanisms underlying heart failure (HF). Carbohydrate Antigen 125 (CA125) is a well-established biomarker in HF, primarily associated with congestion, but also it may act as a functional ligand amplifying the inflammatory response in HF. Our aim was to evaluate the potential modulatory effect of CA125 on inflammation, assessed by a set of cytokines (interleukin [IL]-6, IL-10, IL-1β, and tumor necrosis factor [TNF]). We prospectively included 284 patients admitted for acute HF in which cytokines and CA125 were assessed at admission. Study endpoints were all-cause mortality and total HF rehospitalizations. At a median follow-up of 4.2 years (interquartile range: 1.3-7.5), a total of 211 patients (74.3%) died, and 117 patients (41.2%) experienced 249 HF readmissions. In the multivariable analysis, a significant interaction between IL-6 and IL-10 and CA125 was observed for both outcomes (p -value for interactions < 0.05 for all comparisons). Among patients with CA125 > 35 U/mL, both IL-6 and IL-10 showed a positive, linear relationship with the risk of death or HF readmissions. In contrast, we did not find a significant association in patients with CA125 ≤ 35 U/mL. In conclusion, the association between IL-6 and IL-10 with long-term adverse events was significantly modulated by CA125 status, being significantly associated with poor prognosis only when CA125 was upregulated. These findings support a potential modulatory role for CA125 in the inflammatory response in HF.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Modulating Effect of Carbohydrate Antigen 125 on the Prognostic Value of High-Sensitivity C-Reactive Protein in Heart Failure

  • Santas, Enrique
  • Martí-Martínez, Arancha
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Villar, Sandra|||0000-0001-8229-6279
  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Palau, Patricia|||0000-0001-5040-0924
  • Llàcer-Iborra, Pau|||0000-0002-0988-0599
  • Miñana, Gema|||0000-0001-8777-2588
  • Rodriguez-Borja, Enrique|||0000-0002-0339-6704
  • Carratala, Arturo|||0000-0003-4513-7214
  • González, Arantxa|||0000-0001-5986-6528
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Sanchis, Juan|||0000-0003-0797-8709
  • Núñez, Julio|||0000-0003-1672-7119
Inflammation and congestion are key pathophysiological processes in heart failure (HF). Our aim was to evaluate the potential modulatory effect of carbohydrate antigen 125 (CA125) on inflammation, assessed by high-sensitivity C-reactive protein (hs-CRP). We analyzed a cohort of 4043 consecutive patients in whom hs-CRP and CA125 levels were measured during a hospitalization for acute HF. Multivariate Cox regression models were applied to assess the association between the biomarkers and all-cause mortality and death/HF rehospitalization at 6 months. In multivariable analysis, a significant interaction between hs-CRP and CA125 was observed for both outcomes (p -value for interaction = 0.036 and <0.001, respectively). hs-CRP was significantly associated with an increased risk of death (HR = 1.27; 95% CI 1.16-1.41; p < 0.001) and death/HF rehospitalization (HR = 1.18; 95% CI 1.09-1.28; p < 0.001) if CA125 > 35 U/mL. In contrast, hs-CRP was not predictive of events when CA125 ≤ 35 U/mL. In conclusion, in patients with acute HF, the association between hs-CRP and clinical outcomes was modulated by CA125 levels. hs-CRP was associated with a higher risk of events only in patients with elevated CA125. These findings support a potential modulatory and amplifying role for CA125 in the inflammatory response in HF.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Role of Antigen Carbohydrate 125 in Modulating Soluble ST2, Prognostic-Related Effects in Acute Heart Failure

  • Martí-Martínez, Arancha
  • Núñez, Julio|||0000-0003-1672-7119
  • López Escribano, Herminio
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Mollar, Anna
  • Peiró, Marta
  • Sanchis, Juan|||0000-0003-0797-8709
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Carratala, Arturo|||0000-0003-4513-7214
  • Miró, Oscar|||0000-0002-7924-9751
  • Llorens Soriano, Pere|||0000-0002-9291-7179
  • Herrero-Puente, Pablo|||0000-0002-5529-5008
Background: Acute heart failure (AHF) is a complex syndrome associated with high mortality and hospital readmissions, characterized by volume overload and inflammation. Soluble ST2 (sST2) and antigen carbohydrate 125 (CA125) are emerging biomarkers that reflect these processes and may interact to influence long-term outcomes in AHF patients. This study aims to examine the prognostic relationship between sST2 and CA125 in predicting mortality and heart failure (HF)-related hospitalizations in patients with decompensated heart failure. Methods: In a cohort of 635 patients with AHF, we investigated whether the prognostic value of sST2 varies according to CA125 levels (≤35 vs. >35 U/mL). The endpoints were: (a) time to all-cause death, and (b) the combination of time to death or new HF admission. Results: This study of EAHFE registry data shows that the association between sST2 and long-term adverse outcomes (mortality and HF hospitalizations) in patients with AHF was differentially influenced by CA125 concentrations (p-value for interactions = 0.031 and 0.029, respectively). Higher sST2 was associated with the risk of death and the combined risk of death/HF readmission when CA125 was >35 U/mL [HR = 1.02 (CI 95%: 1.01-1.04), p = 0.006 and 1.02 (CI 95%: 1.01-1.03); p = 0.013 per increase in 10 ng/mL, respectively], but not when CA125 was ≤35 U/mL. Conclusions: This study highlights the prognostic interaction between sST2 and CA125 in AHF. Elevated sST2 predicts poor outcomes mainly in patients with high CA125 levels (>35 U/mL), suggesting CA125's role in modulating inflammatory activity in HF. Further research is needed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron, The Myocardial- Trial

  • Núñez, Julio|||0000-0003-1672-7119
  • Miñana, Gema|||0000-0001-8777-2588
  • Cardells, Ingrid
  • Palau, Patricia|||0000-0001-5040-0924
  • Llàcer, Pau
  • Facila Rubio, Lorenzo|||0000-0003-1402-4364
  • Almenar Bonet, Luis|||0000-0002-7710-361X
  • López-Lereu, Maria P.
  • Monmeneu, Jose V.
  • Amiguet, Martina
  • González, Jessika
  • Serrano, Alicia
  • Montagud, Vicente
  • López-Vilella, Raquel
  • Valero, Ernesto
  • García Blas, Sergio
  • Bodi, Vicente|||0000-0001-6425-5828
  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Lupón, Josep|||0000-0002-5601-9611
  • Navarro, Jorge
  • Górriz, Jose Luis|||0000-0002-1134-9051
  • Sanchis, Juan|||0000-0003-0797-8709
  • Chorro, Francisco J.
  • Comín-Colet, Josep|||0000-0001-8780-720X
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Intravenous ferric carboxymaltose () improves symptoms, functional capacity, and quality of life in heart failure and iron deficiency. The mechanisms underlying these effects are not fully understood. The aim of this study was to examine changes in myocardial iron content after administration in patients with heart failure and iron deficiency using cardiac magnetic resonance. Fifty-three stable heart failure and iron deficiency patients were randomly assigned 1:1 to receive intravenous or placebo in a multicenter, double-blind study. T2* and T1 mapping cardiac magnetic resonance sequences, noninvasive surrogates of intramyocardial iron, were evaluated before and 7 and 30 days after randomization using linear mixed regression analysis. Results are presented as least-square means with 95% CI. The primary end point was the change in T2* and T1 mapping at 7 and 30 days. Median age was 73 (65-78) years, with N-terminal pro-B-type natriuretic peptide, ferritin, and transferrin saturation medians of 1690 pg/mL (1010-2828), 63 ng/mL (22-114), and 15.7% (11.0-19.2), respectively. Baseline T2* and T1 mapping values did not significantly differ across treatment arms. On day 7, both T2* and T1 mapping (ms) were significantly lower in the arm (36.6 [34.6-38.7] versus 40 [38-42.1], P =0.025; 1061 [1051-1072] versus 1085 [1074-1095], P =0.001, respectively). A similar reduction was found at 30 days for T2* (36.3 [34.1-38.5] versus 41.1 [38.9-43.4], P =0.003), but not for T1 mapping (1075 [1065-1085] versus 1079 [1069-1089], P =0.577). In patients with heart failure and iron deficiency, administration was associated with changes in the T2* and T1 mapping cardiac magnetic resonance sequences, indicative of myocardial iron repletion. : . Unique identifier: 03398681.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure

  • Núñez, Julio|||0000-0003-1672-7119
  • Núñez, Eduardo
  • Barallat, Jaume|||0000-0003-3493-5958
  • Bodi, Vicente|||0000-0001-6425-5828
  • Miñana, Gema|||0000-0001-8777-2588
  • Pastor, M. Cruz
  • Sanchis, Juan|||0000-0003-0797-8709
  • Lupón, Josep|||0000-0002-5601-9611
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Our aim was to evaluate the association between the soluble form of neprilysin () levels and long-term all-cause, cardiovascular, and acute heart failure () recurrent admissions in an ambulatory cohort of patients with heart failure. has emerged as a new biomarker with promising implications for prognosis and therapy in patients with heart failure. Reducing the recurrent admission rate of heart failure patients has become an important target of public health planning strategies. We measured levels in 1021 consecutive ambulatory heart failure patients. End points were the number of all-cause, cardiovascular, and hospitalizations during follow-up. We used covariate-adjusted incidence rate ratios to identify associations. At a median follow-up of 3.4 years (interquartile range: 1.8-5.7), 391 (38.3%) patients died, 477 (46.7%) patients had 1901 all-cause admissions, 324 (31.7%) patients had 770 cardiovascular admissions, and 218 (21.4%) patients had 488 admissions. The medians for and amino-terminal pro-brain natriuretic peptide were 0.64 ng/mL (interquartile range: 0.39-1.22) and 1248 pg/mL (interquartile range: 538-2825), respectively. In a multivariate setting, the adjusted incidence rate ratios for the top (>1.22 ng/mL) versus the bottom (≤0.39 ng/mL) quartiles of were 1.37 (95% confidence interval: 1.03-1.82), P =0.032; 1.51 (95% confidence interval: 1.10-2.06), P =0.010; and 1.51 (95% confidence interval: 1.05-2.16), P =0.026 for all-cause, cardiovascular, and admissions, respectively. Elevated levels predicted an increased risk of recurrent all-cause, cardiovascular, and admissions in ambulatory patients with heart failure.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Effect of insulin on readmission for heart failure following a hospitalization for acute heart failure

  • Bertomeu-González, Vicente|||0000-0001-5309-0562
  • Facila Rubio, Lorenzo|||0000-0003-1402-4364
  • Palau, Patricia|||0000-0001-5040-0924
  • Miñana, Gema|||0000-0001-8777-2588
  • Núñez, Gonzalo
  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Santas, Enrique
  • Núñez, Eduardo
  • Bodi, Vicente|||0000-0001-6425-5828
  • Chorro, Francisco J.
  • Cordero, Alberto|||0000-0003-0000-7109
  • Sanchis, Juan|||0000-0003-0797-8709
  • Lupón, Josep|||0000-0002-5601-9611
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Núñez, Julio|||0000-0003-1672-7119
Type 2 diabetes mellitus (T2DM) is common in patients with heart failure (HF) and is related with worse outcomes. Insulin treatment is associated with sodium and water retention, weight gain, and hypoglycaemia-all pathophysiological mechanisms related to HF decompensation. This study aimed to evaluate the association between insulin treatment and the risk of 1 year readmission for HF in patients discharged for acute HF. We prospectively included 2895 consecutive patients discharged after an episode of acute HF in a single tertiary hospital. Multivariable Cox regression, adapted for competing events, was used to assess the association between insulin treatment and 1 year readmission for HF in patients discharged after acute HF. Participants' mean age was 73.4 ± 11.2 years, 50.8% were women, 44.7% had T2DM [including 527 (18.2%) on insulin therapy], and 52.7% had preserved ejection fraction. At 1 year follow-up, 518 (17.9%) patients had died and 693 (23.9%) were readmitted for HF. The crude risk of readmission for HF was higher in patients on insulin, with no differences in 1 year mortality. After multivariable adjustment, patients on insulin were at significantly higher risk of 1 year readmission for HF than patients with diabetes who were not on insulin (hazard ratio 1.28; 95% confidence interval 1.04-1.59, P = 0.022) and patients without diabetes (hazard ratio 1.26; 95% confidence interval 1.02-1.55, P = 0.035). Following acute HF, patients with T2DM on insulin therapy are at increased risk of readmission for HF. Further studies unravelling the mechanisms behind this association are warranted.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Renal function dynamics following co-administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes

  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Morillas, Herminio
  • Bravo, Rafael
  • Vidal, Verónica
  • Núñez, Eduardo
  • Santas, Enrique
  • Miñana, Gema|||0000-0001-8777-2588
  • Sanchis, Juan|||0000-0003-0797-8709
  • Facila Rubio, Lorenzo|||0000-0003-1402-4364
  • Torres, Francisco
  • Górriz, Jose Luis|||0000-0002-1134-9051
  • Valle, Alfonso
  • Núñez, Julio|||0000-0003-1672-7119
The aim of this study was to evaluate the safety profile in terms of changes in renal function after co-treatment with sacubitril/valsartan and empagliflozin in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF). This multicentre observational analysis included 108 patients with T2D and HFrEF treated with both agents: baseline sacubitril/valsartan (Group A; n = 43), baseline empagliflozin (Group B; n = 42), or both agents initiated simultaneously (Group C; n = 23). The primary endpoint was estimated glomerular filtration rate (eGFR) dynamics across treatment groups. A binary characterization of worsening renal function (WRF)/improved renal function (IRF) was included in the primary endpoint. WRF and IRF were defined as an increase/decrease in serum creatinine ≥ 0.3 mg/dL or GFR ≥ 20%. Changes in quantitative variables were evaluated using joint modelling of survival and longitudinal data (JM). Rates and their treatment differences were determined by Poisson regression. The mean left ventricle ejection fraction and eGFR were 32 ± 6% and 70 ± 28 mL/min/1.73 m 2, respectively. At a median follow-up of 1.01 years (inter-quartile range 0.71-1.50), 377 outpatient visits were recorded. Although there were differences in GFR trajectories over time within each treatment, they did not achieve statistical significance (omnibus P = 0.154). However, when these differences were contrasted among groups, there was a significant decrease in GFR in Group A as compared with Group B (P = 0.002). The contrast between Groups C and B was not significant (P = 0.430). These differences were also reflected when the rates for WRF and IRF were contrasted among treatments. The co-administration of sacubitril/valsartan and empagliflozin in patients with HFrEF and concomitant T2D appears to be safe in terms of renal function.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction

  • Miñana, Gema|||0000-0001-8777-2588
  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Palau, Patricia|||0000-0001-5040-0924
  • Llàcer, Pau
  • Núñez, Eduardo
  • Santas, Enrique
  • Valero, Ernesto
  • Lorenzo, Miguel|||0000-0001-9182-4459
  • Núñez, Gonzalo
  • Bodi, Vicente|||0000-0001-6425-5828
  • Heredia, Raquel
  • Sanchis, Juan|||0000-0003-0797-8709
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Chorro, Francisco J.
  • Núñez, Julio|||0000-0003-1672-7119
We aimed to assess the association between CA125 and the long-term risk of total acute heart failure (AHF) admissions in patients with an index hospitalization with AHF and preserved ejection fraction (HFpEF). We prospectively included 2369 patients between 2008 and 2019 in three centers. CA125 and NT-proBNP were measured during early hospitalization and evaluated as continuous and categorized in quartiles (Q). Negative binomial regressions were used to assess the association with the risk of recurrent AHF admission. The mean age of the sample patients was 76.7 ± 9.5 years and 1443 (60.9%) were women. Median values of CA125 and NT-proBNP were 38.3 (19.0-90.0) U/mL, and 2924 (1590-5447) pg/mL, respectively. During a median follow-up of 2.2 (0.8-4.6) years, 1200 (50.6%) patients died, and 2084 AHF admissions occurred in 1029 (43.4%) patients. After a multivariate adjustment, CA125, but not NT-proBNP, was positively and non-linearly associated with the risk of cumulative AHF-readmission (p < 0.001). Compared to Q1, patients belonging to Q2, Q3, and Q4 showed a stepwise risk increase (IRR = 1.29, 95% CI 1.08-1.55, p = 0.006; IRR = 1.35, 95% CI 1.12-1.63, p = 0.002; and IRR = 1.62, 95% CI 01.34-1.96, p < 0.001, respectively). In conclusion, CA125 predicted the risk of long-term AHF-readmission burden in patients with HFpEF and a recent admission for AHF.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Coronary Revascularization and Long-Term Survivorship in Chronic Coronary Syndrome

  • Gabaldon-Perez, Ana|||0000-0002-2475-0282
  • Marcos Garcés, Víctor|||0000-0001-5565-5547
  • Gavara Doñate, Jose|||0000-0002-3483-7066
  • Rios-Navarro, Cesar|||0000-0002-6405-6279
  • Miñana, Gema|||0000-0001-8777-2588
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Husser, Oliver
  • Sanchis, Juan|||0000-0003-0797-8709
  • Núñez, Julio|||0000-0003-1672-7119
  • Chorro, Francisco J.
  • Bodi, Vicente|||0000-0001-6425-5828
Ischemic heart disease (IHD) persists as the leading cause of death in the Western world. In recent decades, great headway has been made in reducing mortality due to IHD, based around secondary prevention. The advent of coronary revascularization techniques, first coronary artery bypass grafting (CABG) surgery in the 1960s and then percutaneous coronary intervention (PCI) in the 1970s, has represented one of the major breakthroughs in medicine during the last century. The benefit provided by these techniques, especially PCI, has been crucial in lowering mortality rates in acute coronary syndrome (ACS). However, in the setting where IHD is most prevalent, namely chronic coronary syndrome (CCS), the increase in life expectancy provided by coronary revascularization is controversial. Over more than 40 years, several clinical trials have been carried out comparing optimal medical treatment (OMT) alone with a strategy of routine coronary revascularization on top of OMT. Beyond a certain degree of symptomatic improvement and lower incidence of minor events, routine invasive management has not demonstrated a convincing effect in terms of reducing mortality in CCS. Based on the accumulated evidence more than half a century after the first revascularization procedures were used, invasive management should be considered in those patients with uncontrolled symptoms despite OMT or high-risk features related to left ventricular function, coronary anatomy, or functional assessment, taking into account the patient expectations and preferences.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction, a pilot study

  • Miñana, Gema|||0000-0001-8777-2588
  • Núñez, Julio|||0000-0003-1672-7119
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Ríos-Navarro, César
  • Núñez, Eduardo
  • Chorro, Francisco J.
  • López-Lereu, Maria Pilar
  • Monmeneu, Jose Vicente
  • Lupón, Josep|||0000-0002-5601-9611
  • Sanchis, Juan|||0000-0003-0797-8709
  • Bodi, Vicente|||0000-0001-6425-5828
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a therapeutic target for reducing plasma low-density lipoprotein cholesterol. Beyond lipid control, recent findings suggest a deleterious effect of this protein in the pathogenesis of postmyocardial infarction left ventricle remodelling and heart failure-related complications. The aim of this study was to assess the relationship between circulating PCSK9 and 6 month cardiac magnetic resonance imaging-derived left ventricular ejection fraction (LVEF) after a first ST-segment elevation myocardial infarction (STEMI). We prospectively evaluated 40 patients with a first STEMI, LVEF < 50% and treated with primary percutaneous coronary intervention in which PCSK9 was measured 24 h postreperfusion. All patients underwent cardiac magnetic resonance imaging 1 week and 6 months after STEMI. Baseline characteristics were compared across median values of PCSK9. The association between PCSK9 levels and LVEF at 6 months was evaluated by analysis of covariance. The mean age of the sample was 60 ± 12 years and 33 (82.5%) were male patients. The infarct location was anterior in 27 patients (67.5%), and 9 patients (22.5%) were Killip class ≥ II. The mean 1 week and 6 month LVEF were 41 ± 7% and 48 ± 10%, respectively. The mean PCSK9 was 1.93 ± 0.38 U/mL. Testing the association between serum PCSK9 and 6 month LVEF with analysis of covariance revealed an inverse relationship (r = -0.35, P = 0.028). After multivariate adjustment, circulating PCSK9 remained significant and inversely associated with 6 month LVEF (P = 0.002). In patients with a first STEMI with reduced ejection fraction at index admission and treated with primary percutaneous coronary intervention, circulating PCSK9 was associated with lower LVEF at 6 months.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure with Preserved Ejection Fraction

  • Santas, Enrique
  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Chorro, Francisco J
  • Palau, Patricia|||0000-0001-5040-0924
  • Miñana, Gema|||0000-0001-8777-2588
  • Heredia, Raquel
  • Amiguet, Martina
  • Merenciano, Héctor|||0000-0002-1734-0381
  • Sanchis, Juan|||0000-0003-0797-8709
  • Lupón, Josep|||0000-0002-5601-9611
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Núñez, Julio|||0000-0003-1672-7119
Right ventricular dysfunction (RVD) parameters are increasingly important features in heart failure with preserved ejection fraction (HFpEF). We sought to evaluate the prognostic impact of a progressive RVD staging system by combining the tricuspid annular plane systolic excursion (TAPSE) to pulmonary artery systolic pressure (TAPSE/PASP) ratio with functional tricuspid regurgitation (TR) severity. We prospectively included 1355 consecutive HFpEF patients discharged for acute heart failure (HF). Of them, in 471 (34.7%) patients, PASP could not be accurately measured, leaving the final sample size to be 884 patients. Patients were categorized as Stage 1: TAPSE/PASP ≥ 0.36 without significant TR; stage 2: TAPSE/PASP ≥ 0.36 with significant TR; stage 3: TAPSE/PASP < 0.36 without significant TR; and stage 4: TAPSE/PASP < 0.36 with significant TR. By the 1 year follow-up, 207 (23.4%) patients had died. We found a significant and graded association between RVD stages and mortality rates (15.8%, 25%, 31.2%, and 45.4% from stage 1 to stage 4, respectively; log-rank test, p < 0.001). After multivariable adjustment, and compared to stage 1, stages 3 and 4 were independently associated with mortality risk (HR: 1.8219; 95% CI 1.308-2.538; p < 0.001 and HR = 2.2632; 95% CI 1.540-3.325; p < 0.001, respectively). A RVD staging system, integrating TAPSE/PASP and TR, provides a comprehensive and widely available tool for risk stratification in HFpEF.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients

  • Pacho Pacho, Cristina
  • Domingo, Mar|||0000-0002-2935-1272
  • Núñez Aragón, Raquel
  • Lupón, Josep|||0000-0002-5601-9611
  • Núñez, Julio|||0000-0003-1672-7119
  • Barallat, Jaume|||0000-0003-3493-5958
  • Moliner, P.|||0000-0002-5511-8597
  • de Antonio Ferrer, Marta|||0000-0002-4319-797X
  • Santesmases Ejarque, Javier|||0000-0002-1226-1617
  • Cediel, Germán|||0000-0001-9667-7507
  • Roura, Santiago|||0000-0003-4063-9661
  • Pastor, M. Cruz
  • Tor Aguilera, Jordi|||0000-0002-5355-9110
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Heart failure (HF) is associated with a high rate of readmissions within 30 days post-discharge and in the following year, especially in frail elderly patients. Biomarker data are scarce in this high-risk population. This study assessed the value of early post-discharge circulating levels of ST2, NT-proBNP, CA125, and hs-TnI for predicting 30-day and 1-year outcomes in comorbid frail elderly patients with HF with mainly preserved ejection fraction (HFpEF). Blood samples were obtained at the first visit shortly after discharge (4.9 ± 2 days). The primary endpoint was the composite of all-cause mortality or HF-related rehospitalization at 30 days and at 1 year. All-cause mortality alone at one year was also a major endpoint. HF-related rehospitalizations alone were secondary end-points. From February 2014 to November 2016, 522 consecutive patients attending the STOP-HF Clinic were included (57.1% women, age 82 ± 8.7 years, mean Barthel index 70 ± 25, mean Charlson comorbidity index 5.6 ± 2.2). The composite endpoint occurred in 8.6% patients at 30 days and in 38.5% at 1 year. In multivariable analysis, ST2 [hazard ratio (HR) 1.53; 95% CI 1.19-1.97; p = 0.001] was the only predictive biomarker at 30 days; at 1 year, both ST2 (HR 1.34; 95% CI 1.15-1.56; p < 0.001) and NT-proBNP (HR 1.19; 95% CI 1.02-1.40; p = 0.03) remained significant. The addition of ST2 and NT-proBNP into a clinical predictive model increased the AUC from 0.70 to 0.75 at 30 days (p = 0.02) and from 0.71 to 0.74 at 1 year (p < 0.05). For all-cause death at 1 year, ST2 (HR 1.50; 95% CI 1.26-1.80; p < 0.001), and CA125 (HR 1.41; 95% CI 1.21-1.63; p < 0.001) remained independent predictors in multivariable analysis. The addition of ST2 and CA125 into a clinical predictive model increased the AUC from 0.74 to 0.78 (p = 0.03). For HF-related hospitalizations, ST2 was the only predictive biomarker in multivariable analyses, both at 30 days and at 1 year. In a comorbid frail elderly population with HFpEF, ST2 outperformed NT-proBNP for predicting the risk of all-cause mortality or HF-related rehospitalization. ST2, a surrogate marker of inflammation and fibrosis, may be a better predictive marker in high-risk HFpEF.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prognostic Value of New-Generation Troponins in -Segment-Elevation Myocardial Infarction in the Modern Era, The - Study

  • Cediel, Germán|||0000-0001-9667-7507
  • Rueda, Ferran|||0000-0001-5464-4870
  • Garcia Garcia, Cosme|||0000-0001-6330-1677
  • Oliveras, Teresa
  • Labata, Carlos|||0000-0002-4505-0787
  • Serra Flores, Jordi
  • Núñez, Julio|||0000-0003-1672-7119
  • Bodi, Vicente|||0000-0001-6425-5828
  • Ferrer Massot, Marc|||0000-0003-0046-1301
  • Lupón, Josep|||0000-0002-5601-9611
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
In -segment-elevation myocardial infarction (), troponins are not needed for diagnosis: symptoms and data are sufficient to activate percutaneous coronary intervention. This study explored the prognostic value of new-generation troponins in a real-life cohort contemporarily treated for . We studied 1260 consecutive patients with primary treated with percutaneous coronary intervention between February 22, 2011, and August 31, 2015. We collected data on clinical characteristics and major adverse cardiovascular and cerebrovascular events () at 30 days and 1 year. Peak high-sensitivity troponin T and sensitive-contemporary troponin I levels were recorded. s occurred in 75 patients (6.1%) by day 30 and in 124 patients (10.8%) between day 31 and 1 year. A short-term (0-30 days) multivariable Cox regression analysis revealed that age, Killip-Kimball class, and left ventricular ejection fraction were independent predictors of s. In adjusted analysis, peak high-sensitivity troponin T and sensitive-contemporary troponin I were not significant (hazard ratio, 1.23 [95% confidence interval, 0.98-1.54] [ P =0.071]; and hazard ratio, 1.15 [95% confidence interval, 0.93-1.43] [ P =0.200], respectively). A long-term (31 days-1 year) multivariable Cox regression analysis revealed that age, female sex, diabetes mellitus, prior coronary artery disease, Killip-Kimball class, and left ventricular ejection fraction were statistically significantly associated with . However, peak high-sensitivity troponin T and peak sensitive-contemporary troponin I were not significantly associated with (hazard ratio, 1.03 [95% confidence interval, 0.88-1.20] [ P =0.715]; and hazard ratio, 0.99 [95% confidence interval, 0.85-1.15] [ P =0.856], respectively). In the modern era, new-generation troponins do not provide significant prognostic information for predicting clinical events in . We should reconsider the value of serial troponin measurements for risk stratification in STEMI.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The influence of sex and body mass index on the association between soluble neprilysin and risk of heart failure hospitalizations

  • Núñez, Julio|||0000-0003-1672-7119
  • Núñez, Eduardo
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Miñana, Gema|||0000-0001-8777-2588
  • Barallat, Jaume|||0000-0003-3493-5958
  • Bodi, Vicente|||0000-0001-6425-5828
  • Sanchis, Juan|||0000-0003-0797-8709
  • Aimo, Alberto|||0000-0001-9129-9519
  • Emdin, Michele
  • Lupón, Josep|||0000-0002-5601-9611
  • Husser, Oliver
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
A higher neprilysin activity has been suggested in women. In this retrospective analysis, we evaluated the association of sex and body mass index (BMI) with soluble neprilysin (sNEP) and recurrent admissions among 1021 consecutive HF outpatients. The primary and secondary endpoints were the number of HF hospitalizations and all-cause mortality, respectively. The association between sNEP with either endpoint was evaluated across sex and BMI categories (≥ 25 kg/m 2 vs. < 25 kg/m 2). Bivariate count regression (Poisson) was used, and risk estimates were expressed as incidence rates ratio (IRR). During a median follow-up of 6.65 years (percentile 25%-percentile 75%:2.83-10.25), 702 (68.76%) patients died, and 406 (40%) had at least 1 HF hospitalization. Median values of sNEP and BMI were 0.64 ng/mL (0.39-1.22), and 26.9 kg/m 2 (24.3-30.4), respectively. Left ventricle ejection fraction was < 40% in 78.9% of patients, and 28% were women. In multivariable analysis, sNEP (main effect) was positively associated with HF hospitalizations (p = 0.001) but not with mortality (p = 0.241). The predictive value of sNEP for HF hospitalizations varied non-linearly across sex and BMI categories (p -value for interaction = 0.003), with significant and positive effect only on women with BMI ≥ 25 kg/m 2 (p = 0.039). For instance, compared to men, women with sNEP of 1.22 ng/mL (percentile 75%) showed a significantly increased risk (IRRs: 1.26; 95% CI: 1.05-1.53). The interaction analysis for mortality did not support a differential prognostic effect for sNEP (p = 0.072). In conclusion, higher sNEP levels in overweight women better predicted an increased risk of HF hospitalization.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HDL Function and Size in Patients with On-Target LDL Plasma Levels and a First-Onset ACS

  • Cordero, Alberto|||0000-0003-0000-7109
  • Muñoz-García, Natàlia|||0000-0002-2982-8982
  • Padró, Teresa|||0000-0003-1921-954X
  • Vilahur, Gemma|||0000-0002-2828-8873
  • Bertomeu-González, Vicente|||0000-0001-5309-0562
  • Escribano, David
  • Flores, Emilio|||0000-0001-7524-0808
  • Zuazola, Pilar
  • Badimon, Lina|||0000-0002-9162-2459
Patients admitted for acute coronary syndrome (ACS) usually have high cardiovascular risk scores with low levels of high-density lipoprotein cholesterol (HDL-C) and high low-density lipoprotein cholesterol (LDL-C) levels. Here, we investigated the role of lipoprotein functionality as well as particle number and size in patients with a first-onset ACS with on-target LDL-C levels. Ninety-seven patients with chest pain and first-onset ACS with LDL-C levels of 100 ± 4 mg/dL and non-HDL-C levels of 128 ± 4.0 mg/dL were included in the study. Patients were categorized as ACS and non-ACS after all diagnostic tests were performed (electrocardiogram, echocardiogram, troponin levels and angiography) on admission. HDL-C and LDL-C functionality and particle number/size by nuclear magnetic resonance (NMR) were blindly investigated. A group of matched healthy volunteers (n = 31) was included as a reference for these novel laboratory variables. LDL susceptibility to oxidation was higher and HDL-antioxidant capacity lower in the ACS patients than in the non-ACS individuals. ACS patients had lower HDL-C and Apolipoprotein A-I levels than non-ACS patients despite the same prevalence of classical cardiovascular risk factors. Cholesterol efflux potential was impaired only in the ACS patients. ACS-STEMI (Acute Coronary Syndrome-ST-segment-elevation myocardial infarction) patients, had a larger HDL particle diameter than non-ACS individuals (8.4 ± 0.02 vs. 8.3 ± 0.02 and, ANOVA test, p = 0.004). In conclusion, patients admitted for chest pain with a first-onset ACS and on-target lipid levels had impaired lipoprotein functionality and NMR measured larger HDL particles. This study shows the relevance of HDL functionality rather than HDL-C concentration in ACS patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of Integrated Care Management on Clinical Outcomes in Atrial Fibrillation Patients, A Report From the FANTASIIA Registry

  • Esteve-Pastor, María Asunción|||0000-0003-3104-3460
  • Ruiz-Ortiz, Martín|||0000-0002-1479-7044
  • Muñiz, Javier|||0000-0002-3087-2067
  • Roldán-Rabadán, Inmaculada|||0000-0003-1299-5298
  • Otero, Déborah
  • Cequier, Ángel|||0000-0002-3230-0011
  • Bertomeu-Martínez, Vicente|||0000-0002-3553-0963
  • Badimon, Lina|||0000-0002-9162-2459
  • Anguita-Sánchez, Manuel|||0000-0001-7875-7263
  • Lip, Gregory Y. H.|||0000-0002-7566-1626
  • Marín, Francisco|||0000-0001-7246-7708
Background: An integrated and holistic approach is increasingly advocated in patients with atrial fibrillation (AF), based on the "Atrial fibrillation Better Care (ABC) pathway: A, Avoid stroke with anticoagulation; B, better symptom management; C, cardiovascular and comorbidity risk management." The aim of this study was to examine the prevalence of adherence to each component of the ABC pathway and to analyze its impact on long-term prognosis in the "real-world" cohort of AF patients from the FANTASIIA registry. Methods: This prospective study included consecutive AF outpatients anticoagulated with direct oral anticoagulants (DOAC) or vitamin K antagonists (VKA) from June 2013 to October 2014. From the ABC pathway, adherence to the "A criterion" was defined by a time in the therapeutic range (TTR) ≥ 70% or correct dose with DOAC; "B criterion" adherence was defined by a European Heart Rhythm Association (EHRA) Symptom Scale I-II; and "C criterion" adherence was defined as optimized risk factors and comorbidity management. Baseline features and embolic events, severe bleeding, and all-cause and cardiovascular mortality rates up to 3 years of follow-up were analyzed, and a Cox multivariate analysis was performed to investigate the role of each component of the ABC pathway in predicting major events. Results: A total of 1,955 AF patients (age: 74.4 ± 9.4 years; 43.2% female patients) were included in this study: adherence to A criterion was observed in 920 (47.1%) patients; adherence to B criterion was observed in 1,791 (91.6%) patients; and adherence to C criterion was observed in 682 (34.8%) patients. Only 394 (20.2%) of the whole population had good control of AF according to the ABC pathway. After a median follow-up of 1,078 days (IQR: 766-1,113), adherence to A criterion was independently associated with reduced cardiovascular mortality [HR: 0.67, 95%CI (0.45-0.99); p = 0.048] compared with non-adherence. Adherence to the B criterion was independently associated with reduced stroke [HR: 0.28, 95%CI (0.14-0.59); p < 0.001], all-cause mortality [HR: 0.49, 95%CI (0.35-0.69); p < 0.001], cardiovascular mortality [HR: 0.39, 95%CI (0.25-0.62); p < 0.001], and major adverse cardiovascular events (MACE) [HR: 0.41, 95%CI (0.28-0.62); p < 0.001] compared with non-adherence. AF patients with C criterion adherence had a significantly lower risk of myocardial infarction [HR: 0.31, 95%CI (0.15-0.66); p < 0.001]. Fully adherent ABC patients had a significant reduction in MACE [HR: 0.64, 95%CI (0.42-0.99); p = 0.042]. Conclusion: In real-world anticoagulated AF patients from FANTASIIA registry, we observed a lack of adherence to integrated care management of AF following the ABC pathway. AF managed according to the ABC pathway was associated with a significant reduction in adverse outcomes during long follow-up, suggesting the benefit of a holistic and integrated approach to AF management.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Venous Leg Compression for Tissue Decongestion in Patients With Worsening Congestive Heart Failure

  • Civera, Jose
  • Miñana, Gema|||0000-0001-8777-2588
  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Santas, Enrique
  • Sastre, Clara
  • Mollar, Anna
  • Conesa, Adriana
  • Martínez, Ana
  • Núñez, Eduardo
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Núñez, Julio|||0000-0003-1672-7119
Venous leg compression (VLC) with elastic bandages has been proposed as a potentially useful strategy for decreasing tissue congestion. We aimed to evaluate the effect of VLC on short-term changes on intravascular refill, assessed by inferior vena cava (IVC) diameter in patients with worsening heart failure (WHF) requiring parenteral furosemide. Additionally, we sought to evaluate whether early changes in IVC were related to short-term decongestion. This is a prospective study in which we included 20 consecutive ambulatory patients with WHF treated with subcutaneous furosemide and VLC for at least 72 h. The endpoints were (a) short-term changes in IVC, (b) the association between decongestion and 3-h IVC changes following VLC. Changes in continuous endpoints and their longitudinal trajectories were estimated with linear mixed regression models. All analyses were adjusted for multiple comparisons. Following administration of subcutaneous furosemide and VLC, we found a significant increase in 3-h IVC diameter (ΔIVC = 1.6 mm, CI 95%: 0.7-2.5; p < 0.001), with a greater increase in those with baseline IVC≤21 mm (2.4 vs. 0.8 mm; p < 0.001). 3-h intravascular refill (increase in IVC≥2 mm) was associated with greater decongestion (natriuresis, weight, peripheral edemas, and dyspnea) in those with baseline IVC≤21 mm but not when IVC>21 mm (p < 0.05 for all comparisons). In this cohort of patients with congestive WHF treated with subcutaneous furosemide and VLC, we found a greater increase in short-term IVC in those with IVC ≤21 mm at baseline. In this subset of patients, a 3-h increase in IVC≥2 mm was associated with greater short-term decongestion.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prognosis Impact of Diabetes in Elderly Women and Men with Non-ST Elevation Acute Coronary Syndrome

  • Díez-Villanueva, Pablo
  • García-Acuña, Jose María
  • Raposeiras-Roubin, Sergio|||0000-0002-6462-4715
  • Barrabés, José A|||0000-0001-7062-6277
  • Cordero, Alberto|||0000-0003-0000-7109
  • Martínez-Sellés, Manuel|||0000-0003-0289-6229
  • Bardají, Alfredo|||0000-0003-1900-6974
  • Marín, Francisco|||0000-0001-7246-7708
  • Ruiz Nodar, Juan Miguel|||0000-0002-8480-0835
  • Vicente-Ibarra, Nuria
  • Alonso Salinas, Gonzalo L.|||0000-0001-5914-8526
  • Cid-Álvarez, Belén
  • Abu-Assi, Emad|||0000-0003-1568-3118
  • Formiga, Frances
  • Núñez, Julio|||0000-0003-1672-7119
  • Núñez, Eduardo
  • Ariza-Solé, Albert|||0000-0002-0819-6656
  • Sanchis, Juan|||0000-0003-0797-8709
Few studies have addressed to date the interaction between sex and diabetes mellitus (DM) in the prognosis of elderly patients with non-ST-segment elevation acute coronary syndrome (NSTEACS). Our aim was to address the role of DM in the prognosis of non-selected elderly patients with NSTEACS according to sex. A retrospective analysis from 11 Spanish NSTEACS registries was conducted, including patients aged ≥70 years. The primary end point was one-year all-cause mortality. A total of 7211 patients were included, 2,770 (38.4%) were women, and 39.9% had DM. Compared with the men, the women were older (79.95 ± 5.75 vs. 78.45 ± 5.43 years, p < 0.001) and more often had a history of hypertension (77% vs. 83.1%, p < 0.01). Anemia and chronic kidney disease were both more common in women. On the other hand, they less frequently had a prior history of arteriosclerotic cardiovascular disease or comorbidities such as peripheral artery disease and chronic pulmonary disease. Women showed a worse clinical profile on admission, though an invasive approach and in-hospital revascularization were both more often performed in men (p < 0.001). At a one-year follow-up, 1090 patients (15%) had died, without a difference between sexes. Male sex was an independent predictor of mortality (HR = 1.15, 95% CI 1.01 to 1.32, p = 0.035), and there was a significant interaction between sex and DM (p = 0.002). DM was strongly associated with mortality in women (HR: 1.45, 95% CI = 1.18-1.78; p < 0.001), but not in men (HR: 0.98, 95% CI = 0.84-1.14; p = 0.787). In conclusion, DM is associated with mortality in older women with NSTEACS, but not in men.